^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Nailike (olverembatinib) (Bcr-abl tyrosine kinase inhibitor) + lisaftoclax (APG-2575) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1096 - FMS-like tyrosine kinase 3 (FLT3) inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 in preclinical models of FLT3-mutant acute myeloid leukemia (AML)
Published date:
03/10/2021
Excerpt:
Antileukemic activity of HQP1351 was first examined using AML cell lines MV-4-11 and MOLM-13, which harbor FLT3-internal tandem duplication (FLT3/ITD) mutations…In particular, treatment of subcutaneous MV-4-11 xenograft tumors in nude mice with HQP1351 10 mg/kg significantly suppressed tumor growth, with a tumor growth inhibition (TGI) of 72.4%...This antitumor effect was potentiated when APG-2575 was combined with HQP1351, resulting in a TGI of 97.2%...The results provide scientific rationale for clinical development of HQP1351 combined with APG-2575 in patients with FLT3-ITD-mutant AML.
